PRLR and breast cancer: Targeting CDK7 kinase, which is known to regulate both transcription and the cell cycle, and ERα phosphorylation with the THZ1 inhibitor was found to effectively inhibit the transcription of PRLR and cell migration in breast cancer cells (85).